caverject impulse
pfizer new zealand limited - alprostadil 12.8ug equivalent to maximum dose of 10 mcg after reconstitution - powder for injection - 10 mcg - active: alprostadil 12.8ug equivalent to maximum dose of 10 mcg after reconstitution excipient: alfadex hydrochloric acid lactose monohydrate sodium citrate dihydrate sodium hydroxide benzyl alcohol water for injection - the treatment of erectile dysfunction in adult males. may be a useful adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.
caverject
pfizer new zealand limited - alprostadil 11.9ug equivalent to 10 µg/ml after reconstitution.; alprostadil 11.9ug equivalent to 10 µg/ml when reconstituted. - powder for injection - 10 mcg - active: alprostadil 11.9ug equivalent to 10 µg/ml after reconstitution. excipient: hydrochloric acid lactose monohydrate sodium citrate dihydrate sodium hydroxide benzyl alcohol water for injection active: alprostadil 11.9ug equivalent to 10 µg/ml when reconstituted. excipient: alfadex hydrochloric acid lactose monohydrate sodium citrate dihydrate sodium hydroxide - caverject is indicated for the treatment of erectile dysfunction. caverject may be a useful adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.
caverject 10 mcg
pfizer pfe pharmaceuticals israel ltd - alprostadil - powder for solution for injection - alprostadil 10 mcg - alprostadil - alprostadil - for the treatment of erectile dysfunction in adult males, due to neurogenic, vasculogenic, psychogenic or mixed etiology. useful adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.
caverject- alprostadil injection, powder, lyophilized, for solution
pharmacia & upjohn company llc - alprostadil (unii: f5td010360) (alprostadil - unii:f5td010360) - alprostadil 20.5 ug in 1 ml - caverject is indicated for the treatment of erectile dysfunction. caverject is indicated as an adjunct to other diagnostic tests in the diagnosis of erectile dysfunction. caverject is contraindicated: caverject is not indicated for use in females. caverject is not indicated for use in females. safety and effectiveness have not been established in pediatric patients [see warnings and precautions (5.8)] . a total of 341 subjects included in clinical studies were 65 and older. no overall differences in safety and effectiveness were observed between these subjects and younger subjects, and the other reported clinical experience has not identified differences in responses between elderly and younger patients. caverject [kav-er-jeckt]® (alprostadil) for injection, for intracavernosal use your healthcare provider should show you how to prepare and inject caverject the right way before you inject it for the first time. do not try to inject yourself until you have been shown the right way to give your injections b
caverject powder for injection 10 mcgml
pfizer private limited - alprostadil - injection, powder, for solution - 10 mcg/ml - alprostadil 10 mcg/ml
caverject impulse alprostadil 20microgram powder for injection with 0.5ml diluent dual chamber cartridge in single use syringe d
pfizer australia pty ltd - alprostadil, quantity: 40 microgram/ml - injection, solution - excipient ingredients: benzyl alcohol; water for injections - intracavernosal alprostadil (pge1) is indicated for the treatment of erectile dysfunction in adult males. intracavernosal alprostadil may be a useful adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.
caverject impulse alprostadil 10microgram powder for injection with 0.5ml diluent dual chamber cartridge in single use syringe d
pfizer australia pty ltd - alprostadil, quantity: 20 microgram/ml - injection, solution - excipient ingredients: benzyl alcohol; water for injections - intracavernosal alprostadil (pge1) is indicated for the treatment of erectile dysfunction in adult males. intracavernosal alprostadil may be a useful adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.
caverject
pfizer new zealand limited - alprostadil 23ug equivalent to 20 µg/ml after reconstitution.; alprostadil 23ug equivalent to 20 µg/ml after reconstitution. - powder for injection - 20 mcg - active: alprostadil 23ug equivalent to 20 µg/ml after reconstitution. excipient: hydrochloric acid lactose monohydrate sodium citrate dihydrate sodium hydroxide benzyl alcohol water for injection active: alprostadil 23ug equivalent to 20 µg/ml after reconstitution. excipient: alfadex hydrochloric acid lactose monohydrate sodium citrate dihydrate sodium hydroxide - caverject is indicated for the treatment of erectile dysfunction. caverject may be a useful adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.
caverject 20microgram powder and solvent for solution for injection vials
pfizer ltd - alprostadil - powder and solvent for solution for injection - 20microgram
caverject 10microgram powder and solvent for solution for injection vials
pfizer ltd - alprostadil - powder and solvent for solution for injection - 10microgram